KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting...

Related Keywords

The University Of Sydney ,New South Wales ,Australia ,Sydney ,Melbourne ,Victoria ,Australian ,Jane Lowe ,John Friend ,Kazia Therapeutics ,Kazia Therapeutics Limited ,University Of Sydney ,Genentech ,Ir Department ,Olivia Newton John Cancer Research Institute ,Clinical Trials Centre ,Centre For Research Excellence In Brain Cancer ,Research Future Fund ,Prnewswire Kazia Therapeutics Limited ,Trials Group For Neuro ,Therapeutics Limited ,Trials Centre ,Co Operative Trials Group ,Professor Hui Gan ,Research Excellence ,Brain Cancer ,Diffuse Intrinsic Pontine Glioma ,Day One Biopharmaceuticals ,Australian Government ,Medical Research Future Fund ,Grade Gliomas ,Orphan Drug Designation ,Fast Track Designation ,Rare Pediatric Disease Designation ,Orphan Designation ,Chief Executive ,Annual Report ,More Information ,Please Contact ,